Month: August 2024

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Written by Customer Service on August 13, 2024. Posted in Earnings Releases And Operating Results.

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition of economic interests in XACIATO™ (clindamycin phosphate) vaginal gel 2%, and two novel Phase 3 assets, from Daré Bioscience Completed the acquisition of Kinnate Pharmaceuticals, adding several potential royalty streams, as well as more than $9.5 million in non-dilutive capital EMERYVILLE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its second quarter 2024 financial results and highlighted recent activities. “The second quarter was marked by pipeline progress, the realization of several cash milestones, the addition of three commercial or...

Middlefield Banc Corp. Announces 2024 Third-Quarter Cash Dividend Payment

Written by Customer Service on August 13, 2024. Posted in Dividend Reports And Estimates.

MIDDLEFIELD, Ohio, Aug. 13, 2024 (GLOBE NEWSWIRE) — Middlefield Banc Corp. (NASDAQ: MBCN) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per common share. The third-quarter dividend is payable on September 13, 2024, to shareholders of record on August 30, 2024. About Middlefield Banc Corp. Middlefield Banc Corp., headquartered in Middlefield, Ohio, is the Bank holding Company of The Middlefield Banking Company, with total assets of $1.83 billion at June 30, 2024. The Bank operates 21 full-service banking centers and an LPL Financial® brokerage office serving Ada, Beachwood, Bellefontaine, Chardon, Cortland, Dublin, Garrettsville, Kenton, Mantua, Marysville, Middlefield, Newbury, Orwell, Plain City, Powell, Solon, Sunbury, Twinsburg, and Westerville. The Bank also operates a Loan Production...

Notice of Nexstim Plc’s Half-Year Report H1 2024

Written by Customer Service on August 13, 2024. Posted in Public Companies.

Press release, Helsinki, 13 August 2024 at 3 PM (EEST) Notice of Nexstim Plc’s Half-Year Report H1 2024 Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) will publish its half-yearly report for the six months ended 30 June 2024 on Friday 16 August 2024 at approximately 9:00 am Finnish time. The company will hold two live webinars for media, investors, and analysts on Friday 16 August 2024. CEO Mikko Karvinen and CFO Joonas Juokslahti will present the financial and operational results followed by a Q&A session. The first live webinar will be in Finnish, and it takes place at 10:30 am EEST. The second live webinar will be in English at 3 pm EEST. Webinar details: To attend the webinars, please access the webinar pages linked below. Through the same link, you can access webinar registration before the event, the...

The court terminated reorganization proceedings for MPG AgroProduction OÜ

Written by Customer Service on August 13, 2024. Posted in Public Companies.

On 28 November 2023, AS Tallinna Sadam (hereinafter referred to as “Tallinna Sadam”) submitted an application to initiate bankruptcy proceedings of MPG AgroProduction OÜ (hereinafter referred to as “MPG”). On 19 January 2024, the debtor submitted its reorganization application. On 12 August 2024, the reorganization proceedings of MPG were terminated by the Supreme Court’s order. In connection with the termination of MPG’s reorganization proceedings, the bankruptcy proceedings of MPG continue in Harju District Court. Bankruptcy proceedings were initiated on 28 November 2023 based on the application submitted by Tallinna Sadam, as MPG has not fulfilled its contractual obligations for a long time. The total amount of the claims is 3.5 million euros and it mainly consists of the outstanding debt of the...

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Written by Customer Service on August 13, 2024. Posted in Public Companies.

Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies Longer recall intervals for PRO assessments are less burdensome to clinical study participants and may improve data collection compliance SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder (FSAD), has been published by The Journal of Sexual Medicine. Publication Details: Johnson,...

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Written by Customer Service on August 13, 2024. Posted in Earnings Releases And Operating Results.

NAVIGATE trial on track for interim top-line analysis in December 2024NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, “We continued to advance the NAVIGATE Phase 2b/3 trial of belapectin in the first half of 2024. We believe that belapectin can potentially offer a new medical treatment option for the increasing number of patients affected with MASH associated liver cirrhosis and portal hypertension that represents a significant unmet medical need, and we are excited for the planned upcoming interim analysis in December 2024.” Khurram...

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Written by Customer Service on August 13, 2024. Posted in Earnings Releases And Operating Results.

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 targeted in 1H 2025Licensing Activity Continues KANSAS CITY, Kan., Aug. 13, 2024 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended June 30, 2024, and provided a clinical and business update. “Cingulate has achieved major development milestones in the second quarter of 2024 relating to our first product candidate, CTx-1301 for the treatment of ADHD. The combination of the Food and Drug Administration (FDA) clearance for filing for marketing approval and completion of the registration batches keeps...

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

Written by Customer Service on August 13, 2024. Posted in Earnings Releases And Operating Results.

IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30, 2024. Second Quarter and Recent HighlightsOn May 10, 2024, Reneo and OnKure, Inc. entered into a definitive merger agreement to combine the companies in an all-stock transaction (the “Merger”). The Merger is expected to create a Nasdaq-listed, clinical stage biopharmaceutical company focused on advancing OnKure’s portfolio of precision oncology therapies. The Merger and a concurrent $65 million private investment in public equity (PIPE) financing are expected to close in the second half of 2024, subject to receipt...

KP Tissue Releases Second Quarter 2024 Financial Results

Written by Customer Service on August 13, 2024. Posted in Earnings Releases And Operating Results.

Solid results driven by strong revenue MISSISSAUGA, Ontario, Aug. 13, 2024 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q2 2024 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and BonterraTM) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.7% interest in Kruger Products. Kruger Products Q2 2024 Business and Financial HighlightsRevenue was $509.8 million in Q2 2024 compared to $466.3 million in Q2 2023, an increase of $43.5 million or 9.3%. Adjusted EBITDA1 was $65.3 million in...

iLearningEngines Reports Second Quarter 2024 Results

Written by Customer Service on August 13, 2024. Posted in Earnings Releases And Operating Results.

Second quarter revenue grew 33.9% year-over-year to $135.5 million Net loss driven entirely by one-time items; Adjusted EBITDA1 of $4 million BETHESDA, Md., Aug. 13, 2024 (GLOBE NEWSWIRE) — iLearningEngines, Inc. (NASDAQ: AILE) (“iLearningEngines”, “ILE”, or “the Company”), a leader in AI-powered learning and work automation for enterprises, today announced financial results for the second quarter ended June 30, 2024. “We are pleased to report financial results for our first quarter as a publicly traded company,” said Harish Chidambaran, Chief Executive Officer of iLearningEngines. “We delivered 33.9% year-over-year top line revenue growth, including $521 million of annual recurring revenue, up 33% year-over-year. It was an exciting and monumental quarter for the Company as we completed our business combination with Arrowroot Acquisition...

Month: August 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals